Carlsmed Posts 58% Revenue Growth on Strong Spine Surgery Demand

Event summary

  • Q1 2026 revenue hit $16.1M, up 58% YoY, with full-year guidance raised to $72M–$77M.
  • Peer-reviewed study in Global Spine Journal showed 74% reduction in reoperations using aprevo® implants.
  • First procedures performed with corra™ cervical plating system and aprevo® bi-lateral posterior in February.
  • Net loss widened to $8.7M from $5.7M YoY due to rising operating expenses.

The big picture

Carlsmed’s strong Q1 performance reflects growing demand for AI-enabled spine surgery solutions, particularly as healthcare systems seek cost-effective, high-outcome treatments. The company’s ability to translate clinical data into commercial success will be key as it competes with established players in the medical device space. With $97.1M in cash reserves, Carlsmed has runway to invest in innovation, but investors will watch for signs of profitability as expenses climb.

What we're watching

Clinical Validation
How the 74% reduction in reoperations will impact aprevo® adoption and competitive positioning.
Operational Scaling
Whether Carlsmed can sustain growth while managing rising R&D and sales expenses.
Market Penetration
The pace at which corra™ and other new products expand Carlsmed’s share in personalized spine surgery.